Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.

ABSTRACT:

Background

Docetaxel (DOC) and abiraterone (ABI) in the upfront setting have separately improved clinical outcomes for metastatic hormone-sensitive prostate cancer (mHSPC), but there are no studies comparing drug efficacies or the influence of racial disparities.

Materials and methods

We performed a retrospective multicenter review from Winship Cancer Institute at Emory University and Georgia Cancer Center for Excellence at Grady Memorial Hospital (2014-2020) for patients with mHSPC treated with either upfront DOC or ABI. Outcomes evaluated were overall survival (OS), progression-free survival (PFS), and prostate-specific antigen complete response (PSA CR).

Results

A total of 168 patients were included, consisting of 92 (54.8%) Black patients and 76 (45.2%) non-Black

SUBMITTER: Smith KER 

PROVIDER: S-EPMC8571757 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature